However, with CD80-mScarlet CHO cells, we observed significantly lower percentages of transendocytosis in LRBA-deficient patients compared to HD (median, 48.6% vs. 65.5% in HD) (Fig. 4e), which was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). The gene discussed is CD80; the disease is Huntington disease.